EE04264B1 - Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks - Google Patents

Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks

Info

Publication number
EE04264B1
EE04264B1 EEP200100066A EEP200100066A EE04264B1 EE 04264 B1 EE04264 B1 EE 04264B1 EE P200100066 A EEP200100066 A EE P200100066A EE P200100066 A EEP200100066 A EE P200100066A EE 04264 B1 EE04264 B1 EE 04264B1
Authority
EE
Estonia
Prior art keywords
sodium chloride
administration
side effects
substance
preparation
Prior art date
Application number
EEP200100066A
Other languages
English (en)
Estonian (et)
Inventor
Toutain Herv�
Guffroy Magali
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9810043A external-priority patent/FR2782009B1/fr
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of EE200100066A publication Critical patent/EE200100066A/xx
Publication of EE04264B1 publication Critical patent/EE04264B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
EEP200100066A 1998-08-05 1999-08-03 Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks EE04264B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9810043A FR2782009B1 (fr) 1998-08-05 1998-08-05 Utilisation de derives de la comptothecine, avec une toxicite gastro-intestinale reduite
US9631898P 1998-08-12 1998-08-12
PCT/FR1999/001916 WO2000007605A1 (fr) 1998-08-05 1999-08-03 Utilisation de derives de la camptothecine, avec une toxicite gastro-intestinale reduite

Publications (2)

Publication Number Publication Date
EE200100066A EE200100066A (et) 2002-06-17
EE04264B1 true EE04264B1 (et) 2004-04-15

Family

ID=26234482

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100066A EE04264B1 (et) 1998-08-05 1999-08-03 Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks

Country Status (24)

Country Link
US (1) US6476043B1 (es)
EP (1) EP1102594B1 (es)
JP (1) JP2002522392A (es)
KR (1) KR20010072228A (es)
AT (1) ATE217531T1 (es)
AU (1) AU771195B2 (es)
BG (1) BG64641B1 (es)
CA (1) CA2340020A1 (es)
CZ (1) CZ295775B6 (es)
DE (1) DE69901506T2 (es)
DK (1) DK1102594T3 (es)
EA (1) EA002917B1 (es)
EE (1) EE04264B1 (es)
ES (1) ES2176009T3 (es)
GE (1) GEP20043254B (es)
HU (1) HUP0103314A3 (es)
ID (1) ID27253A (es)
IL (1) IL141232A0 (es)
NO (1) NO20010454D0 (es)
NZ (1) NZ509859A (es)
PT (1) PT1102594E (es)
SK (1) SK1732001A3 (es)
TR (1) TR200100331T2 (es)
WO (1) WO2000007605A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270834T3 (es) 1999-05-17 2007-04-16 Cancer Research Ventures Limited Composiciones para mejorar la biodisponibilidad de farmacos administrados oralmente.
CA2295429A1 (en) * 2000-01-06 2001-07-06 Michael Michael Treatment or prevention of diarrhea
CA2556254A1 (en) 2004-02-13 2005-08-25 Kabushiki Kaisha Yakult Honsha Aqueous solution preparation containing camptothecins
US20050197355A1 (en) * 2004-03-02 2005-09-08 Henegar Kevin E. Compounds useful in preparing camptothecin derivatives
JP5170741B2 (ja) 2004-04-27 2013-03-27 ウェルスタット バイオロジクス コーポレイション ウイルスおよびカンプトテシン類を使用する癌の処置
JP2006151950A (ja) * 2004-11-05 2006-06-15 Oto Corporation:Kk 納豆菌培養エキス含有製剤及び納豆菌培養エキスの保存方法
ATE446299T1 (de) * 2005-02-07 2009-11-15 Fermion Oy Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
ES2430375T3 (es) * 2005-02-08 2013-11-20 Fermion Oy Procedimiento para la producción de cloruro de [1,4']bipiperidinil-1'-carbonilo o su clorhidrato
JP5133704B2 (ja) * 2005-02-08 2013-01-30 フェルミオン オサケ ユキチュア 製造方法
CA2503099A1 (en) * 2005-04-18 2006-10-18 Kabushiki Kaisha Yakult Honsha Pharmaceutical compositions containing camptothecins
EP1907015B1 (en) 2005-07-14 2012-01-11 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284579A (en) * 1979-07-17 1981-08-18 The United States Of America As Represented By The Of The Department Of Health & Human Services (N-Phosphonacetyl-L-aspartato)(1,2-diaminocyclchexane)platinum(II) or alkali metal salt
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS58154582A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
CH663353A5 (de) * 1984-03-28 1987-12-15 Joaquin Amat Larraz Mittel gegen krebs.
CA1332413C (en) * 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US5225404A (en) 1989-11-06 1993-07-06 New York University Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
IT1247937B (it) * 1991-05-16 1995-01-05 Ist Naz Ric Sul Cancro Associazione farmaceutica ad attivita' antineoplastica
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
WO1996011005A2 (en) 1994-10-06 1996-04-18 Atlas Leon T Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases

Also Published As

Publication number Publication date
DE69901506D1 (de) 2002-06-20
AU771195B2 (en) 2004-03-18
JP2002522392A (ja) 2002-07-23
KR20010072228A (ko) 2001-07-31
BG64641B1 (bg) 2005-10-31
BG105216A (en) 2001-10-31
ATE217531T1 (de) 2002-06-15
EE200100066A (et) 2002-06-17
IL141232A0 (en) 2002-03-10
DK1102594T3 (da) 2002-08-26
HUP0103314A3 (en) 2002-07-29
CZ295775B6 (cs) 2005-11-16
TR200100331T2 (tr) 2001-07-23
SK1732001A3 (en) 2001-06-11
GEP20043254B (en) 2004-06-25
NO20010454L (no) 2001-01-26
NO20010454D0 (no) 2001-01-26
PT1102594E (pt) 2002-10-31
EP1102594B1 (fr) 2002-05-15
HUP0103314A2 (hu) 2002-01-28
US6476043B1 (en) 2002-11-05
CZ2001382A3 (en) 2001-05-16
WO2000007605A1 (fr) 2000-02-17
DE69901506T2 (de) 2002-11-28
EP1102594A1 (fr) 2001-05-30
ID27253A (id) 2001-03-22
ES2176009T3 (es) 2002-11-16
CA2340020A1 (fr) 2000-02-17
EA002917B1 (ru) 2002-10-31
NZ509859A (en) 2003-09-26
AU5168799A (en) 2000-02-28
EA200100214A1 (ru) 2001-08-27

Similar Documents

Publication Publication Date Title
BR9508554A (pt) Preparação farmaceuticamente estável de oxaliplatina
TR200102603T2 (tr) Antitümör aktiviteye sahip olan kamptotesin türevleri
SE9503143D0 (sv) New preparation
HUP9803044A2 (hu) Ibuprofentartalmú készítmény
MY121517A (en) Anticonvulsant derivatives useful in reducing blood glucose levels
MXPA03011510A (es) Derivados de5-halo-triptamina usados como ligandos de receptores de serotonina 5-ht-6 y/o 5-ht-7.
EE04264B1 (et) Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
TR200101633T2 (tr) Farmasötik bileşim
KR970025615A (ko) 암 전이 억제제
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
NO20031410D0 (no) Antitumorterapi innbefattende distamycinderivater
ES2197781A1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
HUP9802736A2 (hu) 1,4-Dihidropiridin-származékok alkalmazása artériafal ateroszklerózisos degradálódásának megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
DE50005076D1 (de) Pharmazeutische, metamizol enthaltende brauseformulierung
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
MEP1108A (en) Use of specific dose of fondaparinux sodium for the treatment of acs
BR9912765A (pt) Utilização de cloreto de sódio
TR200102262T2 (tr) Koroner müdahale ile ilgili kardiovasküler olayların önlenmesi veya azaltılması için yöntem.
MX9601033A (es) Nanosuspensiones para administracion intravenosa.
UA36163A (uk) Спосіб профілактики олігоануричної форми гострої ниркової недостатності

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

MM4A Lapsed by not paying the annual fees

Effective date: 20070803